New Immune Therapies for Autoimmune Diseases
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
['FUNDING_R01'] · DANA-FARBER CANCER INST · NIH-11140314
This project aims to create new, focused immune treatments for autoimmune diseases like Pemphigus Vulgaris, without broadly suppressing the immune system.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11140314 on ClinicalTrials.gov |
What this research studies
Pemphigus vulgaris is a serious autoimmune disease where the body's immune cells mistakenly attack healthy skin proteins, causing painful blisters. Current treatments often weaken the entire immune system, which can lead to side effects. Our goal is to develop a smarter approach that specifically targets only the harmful immune cells responsible for the disease. We are working to create new immune-based therapies that can precisely remove these specific cells, leaving the rest of your immune system healthy. This targeted method could offer a safer and more effective way to manage conditions like Pemphigus Vulgaris.
Who could benefit from this research
Good fit: Patients with autoimmune diseases like Pemphigus Vulgaris, particularly those with autoantibodies targeting desmoglein-3, would be the focus of future clinical applications.
Not a fit: Patients with autoimmune conditions not driven by specific B-cell autoantibodies or those who do not respond to targeted immune therapies may not receive benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to new treatments for autoimmune diseases that are more targeted, have fewer side effects, and are more effective than current broad immunosuppressive therapies.
How similar studies have performed: While broad immunosuppression is common, this approach focuses on novel, targeted immune-based therapeutics, building on established understanding of autoantibody pathology.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RASHIDIAN, MOHAMMAD — DANA-FARBER CANCER INST
- Study coordinator: RASHIDIAN, MOHAMMAD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.